Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors
Condition(s):Advanced Solid TumorsLast Updated:July 20, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Advanced Solid TumorsLast Updated:July 20, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:September 14, 2022Not yet recruiting
Condition(s):HER-2 Positive Advanced Solid TumorsLast Updated:February 1, 2024Recruiting
Condition(s):Advanced Solid TumorLast Updated:February 20, 2024Recruiting
Condition(s):Advanced Solid TumorsLast Updated:February 24, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:July 7, 2022Recruiting
Condition(s):Advanced Solid TumorLast Updated:June 5, 2023Recruiting
Condition(s):Advanced Solid TumorLast Updated:November 22, 2023Not yet recruiting
Condition(s):Advanced Solid TumorLast Updated:March 14, 2023Recruiting
Condition(s):Advanced Solid TumorsLast Updated:August 2, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.